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CME: Practical solutions 
to the antibiotic 
resistance crisis
Approximately 700  000 people die annually 
from antibiotic-resistant infections worldwide, 
and this will rise to 10 million per year by 2050 
if our current overuse and misuse of antibiotics 
is not curtailed. Moreover, if antibiotics are lost, 
each and every medical procedure that relies on 
antibiotics to prevent or treat infection will be 
affected, changing the face of modern medicine 
as we know it. Far from being a futuristic 
fantasy, this is already being played out in South 
African hospitals, leading to closure of wards, 
cancellation of operating lists, and patients being 
sent home without operations that they need 
because of colonisation with multidrug- or pan-
drug-resistant bacteria. Welcome to the post-
antibiotic era!
This edition of CME focuses on the practical 
measures that we can take to make antibiotic 
prescribing appropriate and what needs to be 
done to prevent infection in the first place, 
thereby negating their need. These interventions, 
along with heightened surveillance and 
reporting of resistance patterns and antibiotic 
usage, form the battle strategy to defend the 
efficacy of antibiotics. The antibiotic pipeline, 
which in terms of new classes of antibiotic has 
been dry for the past 28 years and for antibiotics 
against Gram-negative infections is not 
projected to yield a new antibiotic for the next 
10 - 15 years, cannot be relied on to save the day. 
On the contrary, no antibiotic has lasted more 
than 16 years without resistance developing 
to it. The emphasis is therefore on preserving 
what we have through antibiotic stewardship, an 
intervention that ensures appropriate, optimal 
antibiotic prescribing, without doing harm to 
the patient.
SAMJ: Antimicrobial 
resistance
Ninety years ago, having just discovered 
penicillin, Alexander Fleming fretted about 
antimicrobial resistance (AMR). His concerns 
were well founded – last year, the World 
Health Organization (WHO) declared that 
AMR ‘threatens the achievements of modern 
medicine. A post-antibiotic era – in which 
common infections and minor injuries can 
kill – is a very real possibility for the 21st 
century.’[1] As will be appreciated, some 
clinical isolates of Mycobacterium tuberculosis, 
Neisseria gonorrhoeae, Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii and Pseudomonas 
aeruginosa, and species of Enterobacter, 
Salmonella and Shigella, are now resistant to 
most antibiotics.[2]
Antibiotics are used around the world in 
livestock and fish farming, often in crowded, 
unclean conditions, to facilitate faster growth 
and guarantee a cheap food supply. Resistant 
bacteria can be transferred to humans 
through contact with livestock, through the 
food chain, and through waste water from 
these operations, as well as via wastewater 
from hospitals and pharmaceutical plants.[3]
By 2050, it is reckoned, over 4 million 
deaths in Africa will be attributable to AMR 
(Fig. 1).[4] 
Since 1987 there has been a relative ‘discovery 
void’, with only 12 new antibiotics approved 
since 2000.[5] Because the development of 
antibiotics, from discovery to human trials, is 
difficult and expensive, the current stock of 
antibiotics needs to be conserved and any new 
ones preserved. Last year the Glaxo CEO stated 
that pharma was unlikely to spend research 
funds on discovery of new antibiotics if they 
were to sit on the shelf for fear of development 
of AMR upon their use. Fortunately, ‘several 
small companies, seeking to fill the gap, 
have had new antibiotics approved, and the 
world’s fourth-largest drug company recently 
announced its return to the effort. However, 
major disincentives remain, including the 
difficulty of conducting large clinical trials 
to compare drugs in patients with antibiotic-
resistant infections.’[2]
In May this year, the World Health Assembly 
debates the international response to the AMR 
crisis, namely a Global Action Plan (GAP) 
for AMR.[6] Adoption of the GAP will follow 
a year of consultation between a tripartite 
alliance (comprising the WHO, the Food 
and Agriculture Organization (FAO) and the 
World Organization for Animals (OIE)) with 
governments and all relevant stakeholders.
In this issue of SAMJ we emphasise the 
crisis of AMR, and seek to warn against 
administering antibiotics simply because we 
are unsure of a diagnosis or to satisfy patient 
demand, especially when the infection may 
be viral and not bacterial. This is why we 
are pleased to offer the Working Group of 
the Infectious Diseases Society of Southern 
Africa’s updated recommendations for the 
management of upper respiratory tract 
infections in South Africa,[7] and devote this 
month’s CME to antibiotic stewardship.
In this regard, two editorials are key 
reading,[8,9] as is the research article by McKay 
et al.[10] on community- versus healthcare-
acquired bloodstream infections at Groote 
Schuur Hospital, Cape Town,[10] in which 
local surveillance data are used to support 
empirical choices of antimicrobials following 
assessment of whether the infection is 
community or healthcare acquired. As the 
Lowman editorial[8] confirms, ‘good ol’ 
cloxacillin (a far superior drug to vancomycin 
in the treatment of S. aureus) is still a perfectly 
suitable option in the right patient. Similarly, 
with a <5% ESBL rate for Enterobacteriaceae 
associated with community-acquired BSIs, the 
third- and fourth-generation cephalosporins 
still have an important role to play.’ 
Diabetes in children
For children with type 1 diabetes, certain 
fundamental behaviours are associated 
with better glycaemic control: frequency 
of blood glucose (BG) testing (requiring 
sufficient BG test strips), frequency 
of insulin injections, absence of insulin 
omission, adherence to meal planning, and 
patient-initiated dose adjustments, based 
on BG testing. Three articles[11-13] deal with 
management of diabetes in children and 
point out the sharp contrast between the 
status of patients in the public and private 
sectors. In the public sector children often 
cope without adult assistance and, lacking 
a sufficiency of BG test strips, are unable 
Fig. 1. Deaths attributable to antimicrobial resistance every year by 2050.[4]
EDITOR’S CHOICE
327       May 2015, Vol. 105, No. 5
to undertake any more than rudimentary BG monitoring; in the 
private sector they receive education and dietary and exercise 
advice and have access to the most up-to-date management 
techniques. Davey and Segal[13] insist that restricted access to BG 
test strips – so often the case in the public sector – should not be 
allowed to handicap any patient’s diabetes control efforts. 
The simple bread tag – a menace  
to society
Karro et al.[14] alert us to the dangers of the small rectangle of jagged 
plastic securing the bag containing a loaf of sliced bread. Three infants in 
whom a bread tag had lodged in the laryx or subglottis had to be rescued 
by bronchoscopy. Made of thin plastic, the tags tend to be radiolucent on 
X-ray and may even be missed on both flexible nasopharyngoscopy and 
direct laryngoscopy. The authors advise that until redesigned in a safer 
format, the tags should be removed from the bag of bread and stored out 
of reach of young children, or donated to Bread Tags for Wheelchairs – 
The Wheelchair Foundation,[15] which recycles them to buy wheelchairs.
Idiopathic thrombocytopenic  
purpura (ITP)
First-line treatment of ITP is with oral glucocorticoids, with splenectomy 
employed as second-line treatment. Newer drugs such as rituximab 
and thrombopoeitin agonists have brought the role of splenectomy 
into question, particularly as a lethal late complication may be post-
splenectomy sepsis. Antel et al.[16] in their article ‘Role of splenectomy for 
immune thrombocytopenic purpura (ITP) in the era of new second-line 
therapies and in the setting of a high prevalence of HIV-associated ITP’ 
confirm that splenectomy should remain the second-line treatment for 
ITP in most patients, including those with HIV-associated ITP.
Ocular surface squamous neoplasia
Emerging evidence suggests that ocular surface squamous neoplasia 
(OSSN) that requires surgery may be emerging as an AIDS-defining 
illness in sub-Saharan Africa. A study of OSSN among HIV-infected 
patients in Botswana[17] shows that the annual incidence of OSSN 
increased significantly from 3 cases per 100 000 in 1998 to 7/100 000 
in 2004. The authors report on some 500 patients, more than half of 
whom had AIDS (CD4 counts <200 cells/µL).
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